参考文献/References:
[1] Providencia R,Elliott P,Patel K,et al. Catheter ablation for atrial fibrillation in hypertrophic cardiomyopathy:a systematic review and meta-analysis[J]. Heart,2016,102(19):1533-1543.
[2] Creta A,Elliott P,Earley MJ,et al. Catheter ablation of atrial fibrillation in patients with hypertrophic cardiomyopathy:a European observational multicentre study[J]. Europace,2021,23(9):1409-1417.
[3] Garg L,Gupta M,Sabzwari SRA,et al. Atrial fibrillation in hypertrophic cardiomyopathy:prevalence,clinical impact,and management[J]. Heart Fail Rev,2019,24(2):189-197.
[4] Essayagh B,Resseguier N,Michel N,et al. Left atrial dysfunction as marker of poor outcome in patients with hypertrophic cardiomyopathy[J]. Arch Cardiovasc Dis,2021,114(2):96-104.
[5] Alphonse P,Virk S,Collins J,et al. Prognostic impact of atrial fibrillation in hypertrophic cardiomyopathy:a systematic review[J]. Clin Res Cardiol,2021,110(4):544-554.
[6] Costabel JP,Galve E,Terricabras M,et al. E/e’ ratio and left atrial area are predictors of atrial fibrillation in patients with hypertrophic cardiomyopathy[J]. Echocardiography,2018,35(7):935-940.
[7] Philipson DJ,Rader F,Siegel RJ. Risk factors for atrial fibrillation in hypertrophic cardiomyopathy[J]. Eur J Prev Cardiol,2021,28(6):658-665.
[8] 国家心血管病专家委员会心力衰竭专业委员会,中国医师协会心力衰竭专业委员会,中华医学会心血管分会心力衰竭学组,等. 中国肥厚型心肌病指南2022[J]. 中华心力衰竭和心肌病杂志,2022,6(2):80-105.
[9] Chen X,Dong JZ,Du X,et al. Long-term outcome of catheter ablation for atrial fibrillation in patients with apical hypertrophic cardiomyopathy[J]. J Cardiovasc Electrophysiol,2018,29(7):951-957.
[10] Nie C,Zhu C,Xiao M,et al. Risk factors of pulmonary arterial hypertension and its relationship with atrial fibrillation in patients with obstructive hypertrophic cardiomyopathy[J]. Front Cardiovasc Med,2021,8:666431.
[11] Falasconi G,Pannone L,Slavich M,et al. Atrial fibrillation in hypertrophic cardiomyopathy:pathophysiology,diagnosis and management[J]. Am J Cardiovasc Dis,2020,10(4):409-418.
[12] Lee SP,Ashley EA,Homburger J,et al. Incident atrial fibrillation is associated with MYH7 sarcomeric gene variation in hypertrophic cardiomyopathy[J]. Circ Heart Fail,2018,11(9):e005191.
[13] Du M,Wang X,Zhang A,et al. Prognostic effect of atrial fibrillation on survival in patients with hypertrophic cardiomyopathy:a meta-analysis[J]. J Cardiothorac Surg,2023,18(1):196.
[14] Masri A,Kanj M,Thamilarasan M,et al. Outcomes in hypertrophic cardiomyopathy patients with and without atrial fibrillation:a survival meta-analysis[J]. Cardiovasc Diagn Ther,2017,7(1):36-44.
[15] Camm CF,Camm AJ. Atrial fibrillation and anticoagulation in hypertrophic cardiomyopathy[J]. Arrhythm Electrophysiol Rev,2017,6(2):63-68.
[16] Hodges K,Tang A,Rivas CG,et al. Surgical ablation of atrial fibrillation in hypertrophic obstructive cardiomyopathy:outcomes of a tailored surgical approach[J]. J Card Surg,2020,35(11):2957-2964.
[17] Meng Y,Zhang Y,Liu P,et al. Clinical efficacy and safety of Cox-maze Ⅳ procedure for atrial fibrillation in patients with hypertrophic obstructive cardiomyopathy[J]. Front Cardiovasc Med,2021,8:720950.
[18] Karabulut U,Y?lmaz Can Y,Duygu E,et al. Periprocedural,short-term,and long-term outcomes of alcohol septal ablation in patients with hypertrophic obstructive cardiomyopathy:a 20-year single-center experience[J]. Anatol J Cardiol,2022,26(4):316-324.
[19] Meng X,Wang WY,Gao J,et al. Hypertrophic obstructive cardiomyopathy:comparison of outcomes after myectomy or alcohol ablation[J]. Front Cardiovasc Med,2022,9:755376.
[20] Calkins H,Hindricks G,Cappato R,et al. 2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation[J]. Europace,2018,20(1):e1-e160.
[21] Zheng S,Jiang W,Dai J,et al. Five-year outcomes after catheter ablation for atrial fibrillation in patients with hypertrophic cardiomyopathy[J]. J Cardiovasc Electrophysiol,2020,31(3):621-628.
[22] Zhao DS,Shen Y,Zhang Q,et al. Outcomes of catheter ablation of atrial fibrillation in patients with hypertrophic cardiomyopathy:a systematic review and meta-analysis[J]. Europace,2016,18(4):508-520.
[23] Akita K,Suwa K,Urushida T,et al. Combined ablation for paroxysmal atrial fibrillation and drug-refractory hypertrophic obstructive cardiomyopathy:a case report[J]. Eur Heart J Case Rep,2021,5(2):ytaa570.
[24] Liu L,Li J,Zuo L,et al. Percutaneous intramyocardial septal radiofrequency ablation for hypertrophic obstructive cardiomyopathy[J]. J Am Coll Cardiol,2018,72(16):1898-1909.
[25] Lawrenz T,Lawin D,Radke K,et al. Acute and chronic effects of endocardial radiofrequency ablation of septal hypertrophy in HOCM[J]. J Cardiovasc Electrophysiol,2021,32(10):2617-2624.
[26] Albano BB,Fadreguilan EC,Chua JM,et al. Treating a structural heart disease using a non-structural approach:role of cardiac pacing in hypertrophic cardiomyopathy[J]. Cardiol Res,2017,8(1):20-25.
[27] Mathai S,Williams L. Left ventricular outflow tract obstruction in hypertrophic cardiomyopathy and the impact of mavacamten[J]. Ther Adv Chronic Dis,2022,13:20406223221136074.
相似文献/References:
[1]贺鹏康,周菁.心房颤动治疗新技术——冷冻球囊消融[J].心血管病学进展,2016,(1):1.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.001]
HE Pengkang,ZHOU Jing.Cryoballoon Ablation, A Novel Technology for Atrial Fibrillation Treatment[J].Advances in Cardiovascular Diseases,2016,(1):1.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.001]
[2]都明辉,施海峰*,佟佳宾,等.心房颤动消融相关性无症状性脑缺血[J].心血管病学进展,2016,(1):3.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.002]
DU Minghui,SHI Haifeng*,TONG Jiabin,et al.Silent Cerebral Ischemia Related to Atrial Fibrillation Ablation[J].Advances in Cardiovascular Diseases,2016,(1):3.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.002]
[3]郑环杰,综述,肖骅,等.心房颤动抗栓治疗研究进展[J].心血管病学进展,2016,(2):142.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.012]
ZHENG Huanjie,XIAO Hua.Progress of Antithrombotic Therapy in Patients with Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(1):142.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.012]
[4]张清,综述,罗素新,等.新型Xa 因子抑制剂———依度沙班在心房颤动患者抗凝治疗中的研究进展[J].心血管病学进展,2016,(2):151.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.014]
ZHANG Qing,LUO Suxin,TANG Jiong.Novel Factor Xa Inhibitors—Edoxaban in Prevention of Stroke in
Patients with Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(1):151.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.014]
[5]胡红玲,综述,罗素新,等.预防非瓣膜性心房颤动性脑卒中的治疗新进展[J].心血管病学进展,2016,(3):250.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.009]
HU Hongling,LUO Suxin.New Progress in the Treatment for Cerebral Apoplexy of Nonvalvular
Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(1):250.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.009]
[6]王超,杨国澍,综述,等.关附甲素治疗心房颤动的研究进展[J].心血管病学进展,2016,(3):254.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.010]
WANG Chao,YANG Guoshu,CAI Lin,et al.Research Progress of the Treatment of Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(1):254.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.010]
[7]徐小东,综述,杨东辉,等.决奈达隆治疗心房颤动的现状及展望[J].心血管病学进展,2016,(4):368.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.011]
XU Xiaodong,YANG Donghui.Status and Prospect of Dronedarone in Treating Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(1):368.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.011]
[8]冯坤,刘春霞,熊峰,等.超声心动图在肥厚型心肌病诊治中的应用进展[J].心血管病学进展,2016,(4):409.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.021]
FENG Kun,LIU Chunxia,XIONG Feng,et al.Progress in Application of Echocardiography in
Diagnosis and Treatment of Hypertrophic Cardiomyopathy[J].Advances in Cardiovascular Diseases,2016,(1):409.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.021]
[9]张莎,储国俊,吴弘.经导管左心耳封堵术的临床应用进展[J].心血管病学进展,2015,(5):547.[doi:10.3969/j.issn.1004-3934.2015.05.006]
ZHANG Sha,CHU Guojun,WU Hong.Clinial Application Advances in Left Atrial Appendage Closure[J].Advances in Cardiovascular Diseases,2015,(1):547.[doi:10.3969/j.issn.1004-3934.2015.05.006]
[10]汪俊,杨浩.心房颤动射频消融的术式演变[J].心血管病学进展,2015,(5):574.[doi:10.3969/j.issn.1004-3934.2015.05.013]
WANG Jun,YANG Hao.Evolution of Radiofrequency Ablation of Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2015,(1):574.[doi:10.3969/j.issn.1004-3934.2015.05.013]
[11]马秀英 贾锋鹏.肥厚型心肌病并发心房颤动的危险因素研究进展[J].心血管病学进展,2020,(12):1243.[doi:10.16806/j.cnki.issn.1004-3934.2020.12.005]
MA XiuyingJIA Fengpeng.Update about the Risk Factors of Hypertrophic Cardiomyopathy Complicated with Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2020,(1):1243.[doi:10.16806/j.cnki.issn.1004-3934.2020.12.005]
[12]邓清文,何森.肥厚型心肌病合并心房颤动的研究进展[J].心血管病学进展,2021,(4):27.[doi:10.16806/j.cnki.issn.1004-3934.2021.04.010]
DENG Qingwen,HE Sen.Hypertrophic Cardiomyopathy Complicated with Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2021,(1):27.[doi:10.16806/j.cnki.issn.1004-3934.2021.04.010]
[13]李珂 赵海娟 赵耀 黄松群 郭志福.肥厚型心肌病合并心房颤动的导管消融[J].心血管病学进展,2022,(5):399.[doi:10.16806/j.cnki.issn.1004-3934.2022.05.004]
LI Ke,ZHAO Haijuan,ZHAO Yao,et al.Catheter Ablation of Hypertrophic Cardiomyopathy with Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2022,(1):399.[doi:10.16806/j.cnki.issn.1004-3934.2022.05.004]
[14]彭韵朴 谭震 刘磊 刘益均 任宏强.肥厚型心肌病合并心房颤动患者的心血管死亡和猝死风险评估[J].心血管病学进展,2024,(11):1051.[doi:10.16806/j.cnki.issn.1004-3934.2024.11.019]
PENG Yunpu,TAN Zhen,LIU Lei,et al.The Risk Assessment of Cardiovascular Death and Sudden Death in Patients with Hypertrophic Cardiomyopathy Combined with Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2024,(1):1051.[doi:10.16806/j.cnki.issn.1004-3934.2024.11.019]